Related Experiment Video

Updated: Jan 22, 2026

Protocol to Create Chronic Wounds in Diabetic Mice
06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

21.6K

Treatment of diabetic wound based on hypoglycemic and antioxidant

Xinyan Li1, Yang Tan2, Jie Li3

  • 1School of Clinical Medicine, Shandong Second Medical University, Weifang, China.

Frontiers in Bioengineering and Biotechnology
|January 21, 2026
PubMed

Insights

Nanomedicine shows promise for treating diabetic ulcers by delivering hypoglycemic agents and antioxidants. This review explores advanced drug delivery systems to improve healing for diabetic wound complications.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Endocrinology

Background:

  • Diabetic ulcers are severe diabetes complications that impede wound healing due to hyperglycemia and reactive oxygen species (ROS).
  • Current treatments face challenges in effectively managing these complex wounds.
  • Nanomedicine presents a novel approach for targeted delivery and enhanced therapeutic outcomes.

Purpose of the Study:

  • To review current therapeutic strategies for diabetic skin injuries.
  • To focus on drug-based therapies (hypoglycemic agents, antioxidants) and advanced drug delivery systems.
  • To guide the development of next-generation nanomedicines for diabetic wound healing.

Main Methods:

  • Systematic review of existing literature on diabetic ulcer treatments.
  • Analysis of therapeutic strategies including hypoglycemic agents and antioxidants.
  • Evaluation of nanomedicine-based drug delivery systems such as hydrogels, nanofibers, and microneedle patches.

Main Results:

  • Nanomedicine offers targeted delivery of therapeutic agents to diabetic ulcers.
  • Advanced drug delivery systems show potential for enhanced efficacy in managing hyperglycemia and ROS.
  • Hydrogels, nanofibers, and microneedle patches are key nanocarriers for diabetic wound treatment.

Conclusions:

  • Nanomedicine holds significant potential for advancing diabetic ulcer treatment.
  • Targeted delivery of hypoglycemic agents and antioxidants via nanocarriers can accelerate wound healing.
  • Further development of nanomedicines is crucial for overcoming challenges in diabetic wound care.
Keywords:
antioxidantdiabetic ulcersdrug delivery systemshypoglycemicnanomedicines

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.7K
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

4.9K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
608
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
822
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
597
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
535
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
875